Beads (2)Antibody (11)
Launched (13)
Mouse (13)
- (13)
- (2)Unconjugated (1)HRP Labeled (1)Acridinium ester Labeled (1)PE Labeled (2)FA Labeled (3)AF488 Labeled (1)Biotin-labeled (1)Europium chelate Labeled (1)
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Praluzatamab ravtansine | CX-2009 | Phase 2 Clinical | Immunogen Inc, Cytomx Therapeutics Inc | Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |






